|
US2021024597A1
|
|
Treatment of myotonic dystrophy
|
|
WO2021048424A1
|
|
Nucleic acid sequence for regulation of transgene expression
|
|
EP3788957A1
|
|
Method, device and apparatus for measuring segmental muscle volume
|
|
CA3105903A1
|
|
Compositions for the treatment of sarcopenia or disuse atrophy
|
|
EP3622889A1
|
|
Method, device and apparatus for measuring diaphragmatic functional parameters
|
|
US2019309305A1
|
|
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
US2018237775A1
|
|
Antisense oligonucleotides and uses thereof
|
|
US2018169130A1
|
|
Combined therapy for duchenne muscular dystrophy
|
|
FR3048082A1
|
|
DEVICE FOR MEASURING A FORCE
|
|
AU2016214244A1
|
|
Treatment of facioscapulohumeral dystrophy
|
